Corporate announcements

We herewith submit the outcome of the meeting of Board of directors held on today i.e on November 03, 2026

We herewith submit the outcome of the meeting of Board of directors held on today i.e on November 03, 2026

We herewith submit the outcome of the meeting of Board of directors held on today i.e on November 03, 2026

Intimation of record date for redemption of CP

Outcome of Board Meeting held for consideration and approval of the Consolidated and Standalone Unaudited Financial Results for the half-year ended 30th September, 2026.

Investors presentation for the financial results for the quarter and half year ended September 30, 2026.

Investors and Analyst Call Transcript

Outcome of Board Meeting held on November 03, 2026

Krsnaa Diagnostics Limited has informed the Exchange about General Updates

With reference to the above subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of M/s. Mahaveer Infoway Limited held on Tuesday, the 3rd day of November, 2026 from 4:00 p.m. to 4:45 p.m. at the registered office of the company the following were duly considered and approved by the Board of Directors: 1. Unaudited financial results for the quarter and year ended 30.09.2026 (Attached) 2. Limited Review Report for the quarter ended 30.09.2026 (Attached)

Northern Arc Capital Limited has informed the Exchange about Investor Presentation

Unaudited Financial Results for the Quater and Half year Ended on 30th Spetember 2026 . Please find the enclosed

Sandur Manganese & Iron Ores Limited has informed the Exchange about Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended30 September 2026

Board of Directors at their meeting held on today allotted 7435491 equity share of Rs.10 each at a premium of Rs. 1/- per share pursuant to conversion of 7435491 warrants issued on May 10, 2025. Further details as per attachment.

BMW Ventures Limited has informed the Exchange that Record date for the purpose of Dividend is 13-Nov-2026.

Please refer the enclosed file

Please refer the enclosed file

Please refer the enclosed file

Please refer the enclosed file

Please refer the enclosed file

Audio Recording of Q2 & H1 FY27 Earnings Conference Call

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for P Ram Meyyappan & PACs

Unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2026

Audio of (Q2/ H1 FY''27) earnings'' call held on November 3, 2026 at 16:00 Hrs. (IST) is uploaded on the website of the Company. Please find enclosed a letter containing weblink for accessing the same.

Amrutanjan Health Care Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

Statement of deviation or variation in the use of proceeds

Shalby Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

Please find attached the statement confirming 'Nil' utilisation of issue proceeds, as no NCDs were issued during the quarter along with the 'Nil' material deviation certificate for the quarter ended September 30, 2026.

Please find attached the statement confirming 'Nil' utilisation of issue proceeds, as no NCDs were issued during the quarter along with the 'Nil' material deviation certificate for the quarter ended September 30, 2026.

Please find attached the statement confirming 'Nil' utilisation of issue proceeds, as no NCDs were issued during the quarter along with the 'Nil' material deviation certificate for the quarter ended September 30, 2026.

Please find attached the statement confirming 'Nil' utilisation of issue proceeds, as no NCDs were issued during the quarter along with the 'Nil' material deviation certificate for the quarter ended September 30, 2026.

Please find attached the statement confirming 'Nil' utilisation of issue proceeds, as no NCDs were issued during the quarter along with the 'Nil' material deviation certificate for the quarter ended September 30, 2026.

Please find attached the statement confirming 'Nil' utilisation of issue proceeds, as no NCDs were issued during the quarter along with the 'Nil' material deviation certificate for the quarter ended September 30, 2026.

Please find attached the statement confirming 'Nil' utilisation of issue proceeds, as no NCDs were issued during the quarter along with the 'Nil' material deviation certificate for the quarter ended September 30, 2026.

Please find attached the statement confirming 'Nil' utilisation of issue proceeds, as no NCDs were issued during the quarter along with the 'Nil' material deviation certificate for the quarter ended September 30, 2026.

Please find attached the statement confirming 'Nil' utilisation of issue proceeds, as no NCDs were issued during the quarter along with the 'Nil' material deviation certificate for the quarter ended September 30, 2026.

Please find attached the statement confirming 'Nil' utilisation of issue proceeds, as no NCDs were issued during the quarter along with the 'Nil' material deviation certificate for the quarter ended September 30, 2026.

Please find attached the statement confirming 'Nil' utilisation of issue proceeds, as no NCDs were issued during the quarter along with the 'Nil' material deviation certificate for the quarter ended September 30, 2026.

Please find attached the statement confirming 'Nil' utilisation of issue proceeds, as no NCDs were issued during the quarter along with the 'Nil' material deviation certificate for the quarter ended September 30, 2026.

Please find attached the statement confirming 'Nil' utilisation of issue proceeds, as no NCDs were issued during the quarter along with the 'Nil' material deviation certificate for the quarter ended September 30, 2026.

Please find attached the statement confirming 'Nil' utilisation of issue proceeds, as no NCDs were issued during the quarter along with the 'Nil' material deviation certificate for the quarter ended September 30, 2026.

Please find attached the statement confirming 'Nil' utilisation of issue proceeds, as no NCDs were issued during the quarter along with the 'Nil' material deviation certificate for the quarter ended September 30, 2026.

Please find attached the statement confirming 'Nil' utilisation of issue proceeds, as no NCDs were issued during the quarter along with the 'Nil' material deviation certificate for the quarter ended September 30, 2026.

Please find attached the statement confirming 'Nil' utilisation of issue proceeds, as no NCDs were issued during the quarter along with the 'Nil' material deviation certificate for the quarter ended September 30, 2026.

Please find attached the statement confirming 'Nil' utilisation of issue proceeds, as no NCDs were issued during the quarter along with the 'Nil' material deviation certificate for the quarter ended September 30, 2026.

Please find attached the statement confirming 'Nil' utilisation of issue proceeds, as no NCDs were issued during the quarter along with the 'Nil' material deviation certificate for the quarter ended September 30, 2026.

Please find attached the statement confirming 'Nil' utilisation of issue proceeds, as no NCDs were issued during the quarter along with the 'Nil' material deviation certificate for the quarter ended September 30, 2026.

Please find attached the statement confirming 'Nil' utilisation of issue proceeds, as no NCDs were issued during the quarter along with the 'Nil' material deviation certificate for the quarter ended September 30, 2026.

Please find attached the statement confirming 'Nil' utilisation of issue proceeds, as no NCDs were issued during the quarter along with the 'Nil' material deviation certificate for the quarter ended September 30, 2026.

Please find attached the statement confirming 'Nil' utilisation of issue proceeds, as no NCDs were issued during the quarter along with the 'Nil' material deviation certificate for the quarter ended September 30, 2026.